BioCentury
ARTICLE | Company News

Zejula included on CDF

June 15, 2018 4:20 PM UTC

The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Zejula niraparib from Tesaro Inc. (NASDAQ:TSRO) within the country's Cancer Drugs Fund (CDF) to treat relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to the most recent course of platinum-based chemotherapy in adults under a managed access agreement. NICE recommended the oral PARP inhibitor for women with a BRCA mutation who have received two lines of chemotherapy and in women without a BRCA mutation who have received two or more lines of chemotherapy.

The agency noted that overall survival (OS) data are not available and under the managed access agreement, the company will continue to collect OS data through 2020. ...

BCIQ Company Profiles

Merck & Co. Inc.

Tesaro Inc.